Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2009

01-03-2009 | Case Report

‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring

Authors: A. Kühnemund, P. Liebisch, K. Bauchmüller, A. zur Hausen, H. Veelken, R. Wäsch, M. Engelhardt

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2009

Login to get access

Abstract

Purpose

More intensive and novel therapy options in multiple myeloma (MM) hold the promise to improve treatment outcome. However, disease evolution, induced with long disease duration and extensive pretreatment, has resulted in changes in the biological behaviour of MM and unusual relapse emergence, such as of extramedullary (EM) disease or a shift in secretion from intact immunoglobulin (Ig) to free-light chains (FLCs) only.

Methods

We studied ten patients since 2004, thoroughly assessed relevant patient characteristics, prominent similarities, SFLC-changes, therapy response, mode and speed of progression, and the incidence of light-chain escape (LCE)-MM within our entire myeloma patient cohort. Serum FLCs (SFLCs) were determined via Freelite-assay (Dade-Behringer Nephelometer).

Results

This report summarizes the to date largest series of ten patients, whose MM appeared stable, as judged by conventional monitoring of intact Ig levels, but developed severe organ dysfunction as a consequence of initially undetected LC-progression. Median number of anti-MM cycles before LCE occurrence was six, including autologous and/or allogeneic stem cell transplants and novel drugs, predominantly thalidomide, in 4/10. Classic diagnostics, such as electrophoresis and quantitative Ig measurement proved futile to detect LC-progression, whereas SFLCs were reliable markers. The LCE-MM prevalence within 407 MM patients treated in our institution between 2004 and 2007 was 2.46%.

Conclusions

Our report suggests that early detection of LCE-MM by means of serial SFLC measurements may prevent unnecessary complications, allows to detect unusual relapse manifestations in the era of intensive and biological therapy options and possibly also permits to improve treatment results in LCE-MM.
Literature
go back to reference Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JL, Daviet A et al (1999) High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24(1):9–15. doi : 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JL, Daviet A et al (1999) High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24(1):9–15. doi : 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K
go back to reference Haas PS, Bauchmuller K, Kuhnemund A, Finke J, Ihorst G, Engelhardt M (2006) Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 85(3):191–193. doi:10.1007/s00277-005-0040-x PubMedCrossRef Haas PS, Bauchmuller K, Kuhnemund A, Finke J, Ihorst G, Engelhardt M (2006) Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 85(3):191–193. doi:10.​1007/​s00277-005-0040-x PubMedCrossRef
go back to reference Haas PS, Denz U, Ihorst G, Engelhardt M (2008) Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 80(4):303–309 Haas PS, Denz U, Ihorst G, Engelhardt M (2008) Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 80(4):303–309
go back to reference Kuipers J, Vaandrager JW, Weghuis DO, Pearson PL, Scheres J, Lokhorst HM et al (1999) Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 109(2):99–107. doi:10.1016/S0165-4608(98)00157-5 PubMedCrossRef Kuipers J, Vaandrager JW, Weghuis DO, Pearson PL, Scheres J, Lokhorst HM et al (1999) Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 109(2):99–107. doi:10.​1016/​S0165-4608(98)00157-5 PubMedCrossRef
go back to reference Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109(7):2767–2772PubMed Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109(7):2767–2772PubMed
go back to reference Sakai A, Kawano MM, Tanabe O, Kuramoto A (1993) A possible mechanism of inability of immunoglobulin heavy-chain production in Bence-Jones type myeloma cells. Int J Hematol 59(1):31–40PubMed Sakai A, Kawano MM, Tanabe O, Kuramoto A (1993) A possible mechanism of inability of immunoglobulin heavy-chain production in Bence-Jones type myeloma cells. Int J Hematol 59(1):31–40PubMed
go back to reference Szczepanski T, Van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ (2000) Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(-) subgroup of multiple myeloma. Blood 96(3):1087–1093PubMed Szczepanski T, Van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ (2000) Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(-) subgroup of multiple myeloma. Blood 96(3):1087–1093PubMed
go back to reference Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M (2004) Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34(12):1057–1065. doi:10.1038/sj.bmt.1704713 PubMedCrossRef Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M (2004) Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34(12):1057–1065. doi:10.​1038/​sj.​bmt.​1704713 PubMedCrossRef
Metadata
Title
‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring
Authors
A. Kühnemund
P. Liebisch
K. Bauchmüller
A. zur Hausen
H. Veelken
R. Wäsch
M. Engelhardt
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0470-7

Other articles of this Issue 3/2009

Journal of Cancer Research and Clinical Oncology 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine